Company intelligence / Profile preview

META Pharmaceuticals

Shenzhen, Guangdong, Chinameta.com ↗

Ownership: Public · META
Development stage: Commercial

Overview

META Pharmaceuticals is pioneering the development of first-in-class small molecule drugs targeting immune cell metabolism for autoimmune diseases and metabolic disorders. Its lead program has received FDA Rare Pediatric Disease Designation for primary hyperoxaluria. The company leverages AI-driven target discovery in partnership with Xtalpi and Crystal Jade to identify novel metabolic protease targets. Several programs are in preclinical or IND-enabling stages; no clinical efficacy results have been published yet.

Therapeutic areas: Metabolic DisordersImmunologyOtherOncologyRare Diseases
Modalities: Small moleculeChemical drugs
Industry: Biotech

Partnerships

Xtalpi (AI-powered drug design/development partner)Crystal Jade (AI drug development collaboration)

Financials

Market cap: $1.6T
Total revenue: $60.8B
Enterprise value: $1.6T

Beyond the preview

Go deeper on META Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on META Pharmaceuticals.

Explore the full profile